Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Lung Cancer

  Free Subscription

Articles published in Anticancer Res

Retrieve available abstracts of 157 articles:
HTML format

Single Articles

    November 2023
  1. ITO S, Tsurumi K, Shindo N, Soma S, et al
    Multi-gene Liquid Biopsy to Detect Resistance to First-line Osimertinib in Patients With EGFR-mutated Lung Adenocarcinoma.
    Anticancer Res. 2023;43:5031-5040.
    PubMed     Abstract available

  2. SAKAI K, Kuramoto J, Takahashi T, Kawano Y, et al
    Impact of Locoregional Therapies for Brain Lesions on Survival in Patients With Non-small Cell Lung Cancer With Multiple Extrathoracic Metastases.
    Anticancer Res. 2023;43:5107-5114.
    PubMed     Abstract available

  3. ITO A, Tarukawa T, Suzuki Y, Sakaguchi T, et al
    Clinicopathological and Molecular Characteristics Promoting PD-L1 Expression in Early-stage Lung Adenocarcinoma and Squamous Cell Carcinoma.
    Anticancer Res. 2023;43:5197-5204.
    PubMed     Abstract available

  4. YANG T, Si Q, Liu M, DU R, et al
    Novel Biomarker miRNA-625-3p Promotes Cell Proliferation and Metastasis of Lung Adenocarcinoma by Targeting KLF9.
    Anticancer Res. 2023;43:4923-4935.
    PubMed     Abstract available

  5. MATSUDO K, Takenaka T, Hashinokuchi A, Nagano T, et al
    Impact of Chronic Obstructive Pulmonary Disease on the Long-term Prognosis of Patients Undergoing Lobectomy for Non-small-cell Lung Cancer: A Propensity Score-matched Analysis.
    Anticancer Res. 2023;43:5215-5222.
    PubMed     Abstract available

  6. ISOYAMA-SHIRAKAWA Y, Yoshitake T, Ninomiya K, Asai K, et al
    Combination of Clinical Factors and Radiomics Can Predict Local Recurrence and Metastasis After Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer.
    Anticancer Res. 2023;43:5003-5013.
    PubMed     Abstract available

    October 2023
  7. TAMURA T, Numata T, Yanai H, Nakamura R, et al
    Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI).
    Anticancer Res. 2023;43:4583-4591.
    PubMed     Abstract available

  8. SAWABATA N, Morita K, Tatsumi S, Fujii T, et al
    A Novel Filtration Membrane for Clustered Circulating Tumor Cell Extraction: A Prospective Feasibility Study.
    Anticancer Res. 2023;43:4683-4690.
    PubMed     Abstract available

  9. NAGAMINE H, Yashiro M, Yoshimoto N, Izumi M, et al
    RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression.
    Anticancer Res. 2023;43:4663-4672.
    PubMed     Abstract available

  10. ZHAO QI, Ren W, Gao S, Mu N, et al
    Immune Cell Infiltration and Clinical Significance of Angiogenesis-related Genes in Lung Adenocarcinoma.
    Anticancer Res. 2023;43:4473-4489.
    PubMed     Abstract available

    September 2023
  11. ENDO I, Amatya VJ, Kushitani K, Kambara T, et al
    FOXM1 Promotes Mesothelioma Cell Migration and Invasion via Activation of SMAD Signaling.
    Anticancer Res. 2023;43:3961-3968.
    PubMed     Abstract available

  12. SAIJO H, Hirohashi Y, Honjo O, Saikai T, et al
    Anti-CTLA-4 Antibody Might Be Effective Against Non-small Cell Lung Cancer With Large Size Tumor.
    Anticancer Res. 2023;43:4155-4160.
    PubMed     Abstract available

  13. ROSENBROCK J, Lieser A, Ostermann-Myrau J, Judge M, et al
    Efficacy and Toxicity of Robotic Stereotactic Body Radiotherapy of Lung Metastases in Patients With Oligometastatic Disease.
    Anticancer Res. 2023;43:4125-4131.
    PubMed     Abstract available

    August 2023
  14. MIYAHARA N, Hiratsuka M, Okamoto Y, Teishikata T, et al
    Is the Preoperative Prognostic Nutritional Index a Useful Marker for the Decision to Perform Limited Resection in High-risk Patients With Stage I Non-small Cell Lung Cancer?
    Anticancer Res. 2023;43:3659-3664.
    PubMed     Abstract available

  15. LEE YH, Wang SC, Li CH, Chen LH, et al
    The Contribution of DNA Ligase 4 Genetic Variations to Taiwanese Lung Cancer.
    Anticancer Res. 2023;43:3447-3453.
    PubMed     Abstract available

  16. OKAMOTO T, Takenaka T, Yamazaki K, Hamatake M, et al
    Prognostic Impact of Central Nervous System Recurrence After Surgery in Patients With Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer.
    Anticancer Res. 2023;43:3543-3551.
    PubMed     Abstract available

  17. HUNT A, Haque W, Pino R, Farach A, et al
    Radiation Pneumonitis, Really? A Case of Pulmonary Toxicity from CDK4/6 Inhibitor.
    Anticancer Res. 2023;43:3539-3542.
    PubMed     Abstract available

    July 2023
  18. TAN CQY, Ho A, Robinson HA, Huang L, et al
    A Systematic Review of Microwave Ablation for Colorectal Pulmonary Metastases.
    Anticancer Res. 2023;43:2899-2907.
    PubMed     Abstract available

  19. INOMATA M, Matsumoto M, Hayashi K, Seto Z, et al
    Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors.
    Anticancer Res. 2023;43:3241-3246.
    PubMed     Abstract available

  20. KARTALOGLU EB, Oztepe M, Akgun O, Acun T, et al
    Identification of ALX3 Gene Promoter Hypermethylation as a Potential Biomarker for Lung Cancer.
    Anticancer Res. 2023;43:3029-3036.
    PubMed     Abstract available

  21. AOKI M, Kamimura GO, Morizono S, Tokunaga T, et al
    Clinical Significance of Nodal DCsign Expression in Non-small-cell Lung Cancer Patients.
    Anticancer Res. 2023;43:3003-3013.
    PubMed     Abstract available

  22. SASAKI T, Nakamura Y, Hata S, Shimada H, et al
    The GR-SGK1-NDRG1 Pathway as a Predictor of Recurrence and Prognosis in Lung Adenocarcinoma After Radical Surgery.
    Anticancer Res. 2023;43:2965-2974.
    PubMed     Abstract available

  23. CHEN SK, Lee W, Li YC, Hsu FT, et al
    Imipramine Induces Apoptosis and Inhibits the Metastatic Potential of Triple-negative Breast Cancer Cells.
    Anticancer Res. 2023;43:2985-2994.
    PubMed     Abstract available

  24. ZHAO L, Kaser E, Lequio M, D'Mello K, et al
    Say 'No' to Cancer and 'Yes' to Cranberry: The Role of Cranberry Extract in Inhibition of Growth of Lung Adenocarcinoma Cells.
    Anticancer Res. 2023;43:2933-2939.
    PubMed     Abstract available

  25. SUZUKI H, Sasaki E, Tamaki T, Kodaira T, et al
    Association Between 18F-Fluorodeoxyglucose Uptake and Mutation Status of Epidermal Growth Factor Receptor in Sinonasal Tract Cancer.
    Anticancer Res. 2023;43:3247-3253.
    PubMed     Abstract available

    June 2023
  26. KANAOKA K, Tamiya A, Inagaki Y, Taniguchi Y, et al
    Possible False Results With cobas((R)) EGFR Mutation Test v2 and Oncomine Dx Target Test for EGFR Mutation.
    Anticancer Res. 2023;43:2771-2776.
    PubMed     Abstract available

  27. LINARDOU H, Lampaki S, Koliou GA, Vozikis A, et al
    Real-world Data and Economic Evaluation of Nivolumab in Previously Treated Non-small Cell Lung Cancer Greek Patients.
    Anticancer Res. 2023;43:2799-2812.
    PubMed     Abstract available

    May 2023
  28. NAKAHAMA K, Izumi M, Yoshimoto N, Fukui M, et al
    Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data.
    Anticancer Res. 2023;43:2185-2197.
    PubMed     Abstract available

  29. KIM H, Lim DH, Kwon YS, Kim MA, et al
    Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
    Anticancer Res. 2023;43:2343-2349.
    PubMed     Abstract available

  30. NAKAMURA M, Ishikawa H, Ohnishi K, Baba K, et al
    Long-term Outcomes After Moderate Hypofractionated Proton Therapy for Centrally Located Non-small Cell Lung Cancer.
    Anticancer Res. 2023;43:2003-2013.
    PubMed     Abstract available

  31. MOUNTZIOS G, Koumarianou A, Linardou H, Boutis A, et al
    Clinical Outcomes Beyond 1L EGFR-TKI Progression in mNSCLC: Final Results of the Real-World Study 'LUNGFUL'.
    Anticancer Res. 2023;43:2243-2258.
    PubMed     Abstract available

  32. RADES D, Al-Salool A, Bohnet S, Yu NY, et al
    Prevalence of and Risk Factors for Emotional Distress in Patients Undergoing Radiotherapy for Lung Cancer.
    Anticancer Res. 2023;43:2111-2118.
    PubMed     Abstract available

  33. KERROUCH H, Danset M, Hjira N, Kanitakis J, et al
    Metastatic Adenocarcinoma of the Lung Presenting as a Presternal Cutaneous Mass: Case Report and Brief Literature Review.
    Anticancer Res. 2023;43:2367-2370.
    PubMed     Abstract available

    April 2023
  34. JEONG WG, Kim YH, Ahn SJ, Jeong JU, et al
    Effect of Interstitial Lung Abnormality on Concurrent Chemoradiotherapy-treated Stage III Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2023;43:1797-1807.
    PubMed     Abstract available

  35. TANDA M, Yamamoto K, Hori T, Nishiguchi H, et al
    Association of STAT3, CYP3A5, and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients.
    Anticancer Res. 2023;43:1775-1783.
    PubMed     Abstract available

  36. TSUKIOKA T, Izumi N, Komatsu H, Inoue H, et al
    Surgical Outcomes After Pulmonary Resection With Typical or Atypical Bronchoplasty in Patients With Primary Lung Cancer.
    Anticancer Res. 2023;43:1719-1724.
    PubMed     Abstract available

  37. TSUKIOKA T, Izumi N, Komatsu H, Inoue H, et al
    Elevation of the Neutrophil-to-Lymphocyte Ratio Is a Significant Postoperative Poor Prognostic Factor in Patients With Clinical T3-4 Centrally Located Primary Lung Cancer.
    Anticancer Res. 2023;43:1631-1636.
    PubMed     Abstract available

  38. MIYOSHI AI, Ueda Y, Kurita T, Kimura T, et al
    Recent Advances in the Management of Small Cell Carcinoma of the Uterine Cervix.
    Anticancer Res. 2023;43:1397-1405.
    PubMed     Abstract available

    March 2023
  39. MUSA MA, Kolawole Q
    7,8-Diacetoxy-3-(4-methylsulfonylphenyl)-4-phenylcoumarin Induces ROS-dependent Cell Death in the A549 Human Lung Cancer Cell Line.
    Anticancer Res. 2023;43:1001-1007.
    PubMed     Abstract available

  40. TAMIYA A, Tamiya M, Inagaki Y, Taniguchi Y, et al
    Bevacizumab Plus Carboplatin Plus Nab-paclitaxel for Non-squamous Non-small Cell Lung Cancer in a Real-world Setting.
    Anticancer Res. 2023;43:1325-1330.
    PubMed     Abstract available

  41. CHECK JH, Poretta T, Check D, Srivastava M, et al
    Lung Cancer - Standard Therapy and the Use of a Novel, Highly Effective, Well Tolerated, Treatment With Progesterone Receptor Modulators.
    Anticancer Res. 2023;43:951-965.
    PubMed     Abstract available

  42. FANG XQ, Lee S, Kim YS, Han GE, et al
    Streptonigrin Mitigates Lung Cancer-induced Cachexia by Suppressing TCF4/TWIST1-induced PTHLH Expression.
    Anticancer Res. 2023;43:1149-1157.
    PubMed     Abstract available

    February 2023
  43. YAMADA S, Sekine A, Hagiwara E, Onodera Y, et al
    Cumulative Incidence of Thromboembolism and Prognostic Impact of Stroke in BRAF V600E-mutant Non-small-cell Lung Cancer.
    Anticancer Res. 2023;43:935-938.
    PubMed     Abstract available

  44. IKEUCHI N, Igata F, Kinoshita E, Kawabata T, et al
    Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer.
    Anticancer Res. 2023;43:713-724.
    PubMed     Abstract available

  45. ABE T, Iino M, Saito S, Aoshika T, et al
    Comparison of the Efficacy and Toxicity of Concurrent Chemoradiotherapy and Durvalumab and Concurrent Chemoradiotherapy Alone for Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Metastasis.
    Anticancer Res. 2023;43:675-682.
    PubMed     Abstract available

  46. YAMAZAKI M, Komizo N, Iihara H, Hirose C, et al
    Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer.
    Anticancer Res. 2023;43:725-732.
    PubMed     Abstract available

    January 2023
  47. AKINO Y, Shiomi H, Higashinaka N, Kouno T, et al
    Evaluation of Lung and Liver Tumor Dose Coverage Treated With the CyberKnife Synchrony System With Consideration of Measured Tracking Errors.
    Anticancer Res. 2023;43:231-238.
    PubMed     Abstract available

    December 2022
  48. TSUKIOKA T, Izumi N, Komatsu H, Inoue H, et al
    Detailed Surgical Techniques and Short-term Clinical Outcomes of Sleeve Lobectomy for Locally Advanced Right Lower Lobe Lung Cancer.
    Anticancer Res. 2022;42:5977-5982.
    PubMed     Abstract available

  49. LIM CH, Koh YW, Hyun SH, Lee SJ, et al
    A Machine Learning Approach Using PET/CT-based Radiomics for Prediction of PD-L1 Expression in Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:5875-5884.
    PubMed     Abstract available

  50. KASHIWABARA K, Fujii S, Tsumura S, Sakamoto K, et al
    Overall Survival of Small-cell Lung Cancer Patients With Malignant Central Airway Obstruction Who Received Chemotherapy Without Undergoing Transbronchial Interventions: A Single-institution Retrospective Study.
    Anticancer Res. 2022;42:6113-6119.
    PubMed     Abstract available

  51. PARTYNSKA A, Piotrowska A, Pawelczyk K, Rzechonek A, et al
    The Expression of Histone Acetyltransferase KAT6A in Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:5731-5741.
    PubMed     Abstract available

  52. SHIMOMURA K, Yamaguchi T, Oya Y, Uchida K, et al
    Impact of Corticosteroids for IrAEs on the Clinical Outcome of Immunotherapy in Patients With NSCLC.
    Anticancer Res. 2022;42:5961-5969.
    PubMed     Abstract available

    November 2022
  53. SATO K, Nakamura S, Kadomatsu Y, Ueno H, et al
    Neoadjuvant Therapy for Patients With Non-small Cell Lung Cancer Complicated With Chest Wall Invasion.
    Anticancer Res. 2022;42:5539-5546.
    PubMed     Abstract available

    October 2022
  54. DAMEN PJJ, Suijkerbuijk KPM, VAN Lindert ASR, Eppinga WSC, et al
    Long-term Local Control and Overall Survival After Radiotherapy in Oligoprogressive Patients During Treatment With Checkpoint Inhibitors.
    Anticancer Res. 2022;42:4795-4804.
    PubMed     Abstract available

  55. TAKAYAMA Y, Yano J, Seike R, Mishima S, et al
    Efficacy of Chemoimmunotherapy in NSCLC Patients With Brain Metastasis With or Without Prior Brain Radiotherapy.
    Anticancer Res. 2022;42:4805-4812.
    PubMed     Abstract available

  56. MATSUI Y, Yamada T, Morimoto K, Katayama Y, et al
    Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung Cancer.
    Anticancer Res. 2022;42:4921-4928.
    PubMed     Abstract available

    September 2022
  57. HATTORI S, Okauchi S, Sasatani Y, Ohara G, et al
    Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation.
    Anticancer Res. 2022;42:4589-4595.
    PubMed     Abstract available

  58. STOLERIU MG, Stathopoulos G, Stacher-Priehse E, Ketscher C, et al
    Predicting Long-term Survival After Lung Metastasectomy in Patients With Malignant Germ-cell Tumors.
    Anticancer Res. 2022;42:4517-4527.
    PubMed     Abstract available

  59. SUKPRASANSAP M, Chanvorachote P
    Evidence of Potential Plant-derived Compounds With Anticancer Effects on Lung Cancer: Clinical and Molecular Pharmacology Approaches.
    Anticancer Res. 2022;42:4247-4258.
    PubMed     Abstract available

  60. MORITA K, Sawabata N, Tatsumi S, Fujii T, et al
    Verification of A New Filter for Isolation of Circulating Tumor Cells by Only Blood Filtration.
    Anticancer Res. 2022;42:4305-4310.
    PubMed     Abstract available

  61. TAN C, Fisher OM, Huang L, Alzahrani N, et al
    Comparison of Microwave and Radiofrequency Ablation in the Treatment of Pulmonary Metastasis of Colorectal Cancer.
    Anticancer Res. 2022;42:4563-4571.
    PubMed     Abstract available

  62. CHANVORACHOTE P, Petsri K, Thongsom S
    Epithelial to Mesenchymal Transition in Lung Cancer: Potential EMT-Targeting Natural Product-derived Compounds.
    Anticancer Res. 2022;42:4237-4246.
    PubMed     Abstract available

    August 2022
  63. JANPIPATKUL K, Panvongsa W, Worakitchanon W, Reungwetwattana T, et al
    Extracellular Vesicles from EGFR T790M/L858R-mutant Non-small Cell Lung Cancer Promote Cancer Progression.
    Anticancer Res. 2022;42:3835-3844.
    PubMed     Abstract available

  64. LEE YC, Weng YS, Wang HY, Hsu FT, et al
    Magnolol Induces Apoptosis Through Extrinsic/intrinsic Pathways and Attenuates NF-kappaB/STAT3 Signaling in Non-small-cell Lung Cancer Cells.
    Anticancer Res. 2022;42:3825-3833.
    PubMed     Abstract available

    July 2022
  65. RAJHA A, Piso P, Halmy L, Panczel I, et al
    Rare Histologies and Infrequent Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Anticancer Res. 2022;42:3681-3692.
    PubMed     Abstract available

  66. SATO J, Nakano K, Shimizu T, Uchida M, et al
    Evaluation of Durvalumab-induced Lung Toxicity Using a Spontaneous Reporting Database.
    Anticancer Res. 2022;42:3575-3582.
    PubMed     Abstract available

  67. KIM YJ, Hong SE, Jang SK, Park KS, et al
    Knockdown of NUPR1 Enhances the Sensitivity of Non-small-cell Lung Cancer Cells to Metformin by AKT Inhibition.
    Anticancer Res. 2022;42:3475-3481.
    PubMed     Abstract available

  68. WU MF, Chen LH, Hsia NY, Shen YC, et al
    Significant Contribution of Interleukin-18 Genotypes to Lung Cancer Risk in Taiwanese.
    Anticancer Res. 2022;42:3381-3387.
    PubMed     Abstract available

  69. NAKANO T, Yasumatsu R, Hashimoto K, Kuga R, et al
    Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study.
    Anticancer Res. 2022;42:3653-3664.
    PubMed     Abstract available

  70. SHAM NO, Zhao L, Zhu Z, Roy TM, et al
    Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential Molecular Targets.
    Anticancer Res. 2022;42:3275-3284.
    PubMed     Abstract available

    June 2022
  71. NAKAMURA R, Yoneyama S, Tobita R, Kurihara S, et al
    Effect of Postoperative Muscle Loss After Resection of Non-small Cell Lung Cancer on Surgical Outcomes.
    Anticancer Res. 2022;42:3159-3168.
    PubMed     Abstract available

  72. MATSUMURA K, Yamamura K, Oda E, Akahoshi S, et al
    Successful Treatment of Intrahepatic Cholangiocarcinoma With Liver/Lung Metastasis and Peritoneal Dissemination After Liver Resection.
    Anticancer Res. 2022;42:3209-3215.
    PubMed     Abstract available

  73. SATO J, Uchida M, Wakabayashi H, Shimizu T, et al
    Evaluation of Lung Toxicity Related to the Treatment With Alectinib Using a Pharmacovigilance Database.
    Anticancer Res. 2022;42:3109-3116.
    PubMed     Abstract available

  74. SHAMAVONIAN R, Cheng E, Karpes JB, Barat S, et al
    Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Outcomes and Survival From an Australian Centre.
    Anticancer Res. 2022;42:2939-2944.
    PubMed     Abstract available

  75. HIROSHIMA Y, Tamaki Y, Sawada T, Ishida T, et al
    Stereotactic Body Radiotherapy for Stage I Lung Cancer With a New Real-time Tumor Tracking System.
    Anticancer Res. 2022;42:2989-2995.
    PubMed     Abstract available

  76. BOLLER D, Doepfner KT, Laurentiis A, Guerreiro AS, et al
    Republication: Targeting PI3KC2beta Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours.
    Anticancer Res. 2022;42:3217-3230.
    PubMed     Abstract available

  77. TSUKIOKA T, Izumi N, Komatsu H, Inoue H, et al
    Large Tumor Size and High Neutrophil-to-lymphocyte Ratio Predicts Poor Prognosis After Pneumonectomy or Sleeve Lobectomy in Patients With Non-small-cell Lung Cancer.
    Anticancer Res. 2022;42:3029-3034.
    PubMed     Abstract available

  78. TU CY, Chen HJ, Hsia TC, Fang HY, et al
    Adjuvant Concurrent Chemoradiotherapy Versus Adjuvant Chemotherapy Only in Locally Advanced Non-small-cell Lung Cancer With Involved Microscopic Resection Margin: A Population-based Cohort Study.
    Anticancer Res. 2022;42:3195-3201.
    PubMed     Abstract available

  79. KASHIWAGI K, Sato-Yazawa H, Ishii J, Kohno K, et al
    LXRbeta Activation Inhibits the Proliferation of Small-cell Lung Cancer Cells by Depleting Cellular Cholesterol.
    Anticancer Res. 2022;42:2923-2930.
    PubMed     Abstract available

  80. NAKAMURA M, Ishikawa H, Ohnishi K, Baba K, et al
    Proton Beam Therapy in Elderly Patients With cT1-3N0M0 Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:2953-2960.
    PubMed     Abstract available

  81. NIEDER C, Aanes SG, Haukland EC
    Survival and Early Death Within Three Months from the Start of Immune Checkpoint Inhibitors in Patients With Different Types of Cancer.
    Anticancer Res. 2022;42:3061-3066.
    PubMed     Abstract available

    May 2022
  82. SHIOZAWA T, Numata T, Tamura T, Endo T, et al
    Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:2583-2590.
    PubMed     Abstract available

  83. WATANABE S, Yamazaki H, Kimoto T, Suzuki G, et al
    Repeated Stereotactic Body Radiotherapy for Lung Malignancies: Toxicity Can Be Reduced by Sparing Lung Irradiation.
    Anticancer Res. 2022;42:2701-2709.
    PubMed     Abstract available

  84. BASSANELLI M, Ramella S, Zeuli M, Ceribelli A, et al
    Radiotherapy and Immunotherapy: The Power of the Teamwork for the Treatment of NSCLC.
    Anticancer Res. 2022;42:2241-2247.
    PubMed     Abstract available

    April 2022
  85. CHEN CH, Chang JW, Chang CF, Huang CY, et al
    Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations.
    Anticancer Res. 2022;42:2145-2157.
    PubMed     Abstract available

  86. GLATZEL E, Werner EM, Bohnet S, Rades D, et al
    A Prognostic Tool to Estimate the Risk of Pneumonitis in Patients Irradiated for Lung Cancer.
    Anticancer Res. 2022;42:2029-2032.
    PubMed     Abstract available

  87. SVATON M, Bratova M, Koubkova L, Fischer O, et al
    Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?
    Anticancer Res. 2022;42:1987-1995.
    PubMed     Abstract available

  88. RADES D, Glatzel E, Bohnet S, Schild SE, et al
    Estimating the Probability of Not Completing the Intended Course of Thoracic Radiotherapy for Lung Cancer.
    Anticancer Res. 2022;42:1973-1977.
    PubMed     Abstract available

    March 2022
  89. KIM MH, Choi CM, Lee SY, Park CK, et al
    First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
    Anticancer Res. 2022;42:1615-1622.
    PubMed     Abstract available

  90. SVATON M, Drosslerova M, Fischer O, Marel M, et al
    Laboratory Parameters Associated With Inflammation Do Not Affect PD-L1 Expression in Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:1563-1569.
    PubMed     Abstract available

  91. LI CH, Yang YC, Hsia TC, Shen TC, et al
    Association of Interleukin-8 Promoter Genotypes With Taiwan Lung Cancer Risk.
    Anticancer Res. 2022;42:1229-1236.
    PubMed     Abstract available

  92. II H, Kasahara Y, Yamaguma H, Kageyama S, et al
    Administration of Gapmer-type Antisense Oligonucleotides Targeting gamma-Glutamylcyclotransferase Suppresses the Growth of A549 Lung Cancer Xenografts.
    Anticancer Res. 2022;42:1221-1227.
    PubMed     Abstract available

  93. OTOSHI T, Nagano T, Park J, Hosomi K, et al
    The Gut Microbiome as a Biomarker of Cancer Progression Among Female Never-smokers With Lung Adenocarcinoma.
    Anticancer Res. 2022;42:1589-1598.
    PubMed     Abstract available

  94. YUMURA M, Nagano T, Jimbo N, Dokuni R, et al
    Annexin A10 Expression as a Novel Prognostic Marker in Lung Adenocarcinoma.
    Anticancer Res. 2022;42:1289-1294.
    PubMed     Abstract available

    February 2022
  95. JOGIAT UM, Chu QS, Nagendran J, Laing B, et al
    Bilateral Lung Transplant for Treatment of Idiopathic Pulmonary Fibrosis With Undetected Lung Adenocarcinoma: A Case Report.
    Anticancer Res. 2022;42:1157-1160.
    PubMed     Abstract available

  96. TAKENAKA T, Tagawa T, Kohno M, Haratake N, et al
    Consideration of the Optimal Surgical Procedure Based on the Risk of Recurrence in Clinical Stage 0 or IA Lung Adenocarcinoma.
    Anticancer Res. 2022;42:1137-1142.
    PubMed     Abstract available

  97. HORIUCHI M, Oguri T, Kagawa Y, Sone K, et al
    Differences in the Therapeutic Effect of Chemotherapy Regimens for Concurrent Chemoradiotherapy of Locally Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:1073-1079.
    PubMed     Abstract available

  98. TAKANO N, Seike M, Sugano T, Matsuda K, et al
    A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed.
    Anticancer Res. 2022;42:709-722.
    PubMed     Abstract available

    January 2022
  99. MESSEHA SS, Nezami MA, Hager S, Soliman KFA, et al
    A Rare Presentation of a Non-Asian Female With Metastatic Non-small-cell Lung Cancer Harboring EGFR L747P Mutation With Clinical Response to Multi-targeted Epigenetic and EGFR Inhibition.
    Anticancer Res. 2022;42:441-447.
    PubMed     Abstract available

  100. SAVARESE-BRENNER B, Heugl M, Rath B, Schweizer C, et al
    MUC1 and CD147 Are Promising Markers for the Detection of Circulating Tumor Cells in Small Cell Lung Cancer.
    Anticancer Res. 2022;42:429-439.
    PubMed     Abstract available

  101. HAYASHI K, Suzuki O, Shiomi H, Nakai M, et al
    Stereotactic Ablative Radiotherapy Using CyberKnife for Stage I Non-small-cell Lung Cancer: A Retrospective Analysis.
    Anticancer Res. 2022;42:321-327.
    PubMed     Abstract available

  102. LEE EJ, Park SJ, Lee J, Mun J, et al
    The Clinical Desire for Pressurized Intraperitoneal Aerosol Chemotherapy in South Korea: An Electronic Survey-based Study.
    Anticancer Res. 2022;42:363-371.
    PubMed     Abstract available

  103. YASUDA Y, Nagano T, Jimbo N, Kiriu T, et al
    Chloride Intracellular Channel 1 Expression Is Associated With Poor Prognosis of Lung Adenocarcinoma.
    Anticancer Res. 2022;42:271-277.
    PubMed     Abstract available

  104. ASANO Y, Yamamoto N, Hayashi K, Takeuchi A, et al
    Impact of Tumor Growth Speed of Primary Lesions on the Clinical Outcomes of Appendicular Skeletal Metastases.
    Anticancer Res. 2022;42:229-236.
    PubMed     Abstract available

    December 2021
  105. MUTO S, Inomata S, Yamaguchi H, Mine H, et al
    CTLA-4 Expression in Tumor-infiltrating Lymphocytes Is Irrelevant to PD-L1 Expression in NSCLC.
    Anticancer Res. 2021;41:6267-6272.
    PubMed     Abstract available

  106. PUTRI HE, Sritularak B, Chanvorachote P
    Pongamol Inhibits Epithelial to Mesenchymal Transition Through Suppression of FAK/Akt-mTOR Signaling.
    Anticancer Res. 2021;41:6147-6154.
    PubMed     Abstract available

    November 2021
  107. FUJIWARA M, Doi H, Igeta M, Suzuki H, et al
    Radiation Pneumonitis After Volumetric Modulated Arc Therapy for Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:5793-5802.
    PubMed     Abstract available

  108. SHIMODA Y, Yoshida T, Shirasawa M, Mizuno T, et al
    Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2021;41:5739-5747.
    PubMed     Abstract available

  109. SAITO T, Ohnishi K, Ishikawa H, Nakamura M, et al
    Hypofractionated Proton Beam Therapy for cT1-2N0M0 Non-small Cell Lung Cancer Patients With Interstitial Lung Disease.
    Anticancer Res. 2021;41:5635-5642.
    PubMed     Abstract available

  110. SKRICKOVA J, Pesek M, Opalka P, Koubkova L, et al
    Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:5625-5634.
    PubMed     Abstract available

  111. VENCLICEK O, Skrickova J, Brat K, Fischer O, et al
    Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry.
    Anticancer Res. 2021;41:5549-5556.
    PubMed     Abstract available

  112. KURODA H, Masago K, Takahashi Y, Fujita S, et al
    Positive Correlation Between the Number of Circulating Tumor Cells in the Pulmonary Vein and Tumor Spread Through Air Spaces in Resected Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:5499-5505.
    PubMed     Abstract available

  113. NOJIMA Y, Shimizu K, Saisho S, Maeda AI, et al
    Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:5469-5475.
    PubMed     Abstract available

  114. LIAO WC, Huang CW, Hsia TC, Shen YC, et al
    Association of TIMP-2 Rs8179090 Genotypes With Lung Cancer Risk in Taiwan.
    Anticancer Res. 2021;41:5425-5430.
    PubMed     Abstract available

  115. TSOCHANTARIDIS I, Voulgaridou GP, Giatromanolaki A, Koukourakis MI, et al
    Profiling of Aldehyde Dehydrogenase Isoforms in In Vitro Formed Tumorspheres.
    Anticancer Res. 2021;41:5481-5488.
    PubMed     Abstract available

    October 2021
  116. MATSUBARA T, Hirai F, Yamaguchi M, Hamatake M, et al
    Immunonutritional Indices in Non-small-cell Lung Cancer Patients Receiving Adjuvant Platinum-based Chemotherapy.
    Anticancer Res. 2021;41:5157-5163.
    PubMed     Abstract available

  117. MITSUYA S, Tsuruoka K, Kanaoka K, Funamoto T, et al
    Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
    Anticancer Res. 2021;41:5137-5145.
    PubMed     Abstract available

  118. HAMADA K, Yoshimura K, Hirasawa Y, Hosonuma M, et al
    Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy.
    Anticancer Res. 2021;41:4985-4993.
    PubMed     Abstract available

  119. SON KH, Kim MY, Shin JY, Kim JO, et al
    Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations.
    Anticancer Res. 2021;41:4807-4820.
    PubMed     Abstract available

  120. ARAKI K, Yamamuro N, Tomonobu N, Kumon H, et al
    REIC/Dkk-3 Gene Therapy Induces Immunogenic Cell Death in a Mouse Model of Malignant Mesothelioma.
    Anticancer Res. 2021;41:4837-4855.
    PubMed     Abstract available

  121. VODICKA J, Skala M, Sebek J, Treska V, et al
    The Role of Serum Tumor Markers in Follow-up After Surgical Treatment of Malignant Lung Tumors.
    Anticancer Res. 2021;41:5117-5122.
    PubMed     Abstract available

  122. JANSSEN S, Overhoff D, Froelich MF, Schoenberg SO, et al
    Detectability of Lung Nodules in Ultra-low Dose CT.
    Anticancer Res. 2021;41:5053-5058.
    PubMed     Abstract available

  123. KINOSHITA H, Shimozato O, Ishii T, Kamoda H, et al
    The Thioredoxin Reductase Inhibitor Auranofin Suppresses Pulmonary Metastasis of Osteosarcoma, But Not Local Progression.
    Anticancer Res. 2021;41:4947-4955.
    PubMed     Abstract available

    September 2021
  124. SURAPANENI SK, Nottingham E, Mondal A, Patel N, et al
    Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:4215-4228.
    PubMed     Abstract available

  125. KIM SW, DO SI, Na K
    External Validation of ALK and ROS1 Fusions Detected Using an Oncomine Comprehensive Assay.
    Anticancer Res. 2021;41:4609-4617.
    PubMed     Abstract available

  126. YOSHIDA D, Kusunoki T, Takayama Y, Kusano Y, et al
    Comparison of Dose Distribution Between VMAT-SBRT and Scanning Carbon-ion Radiotherapy for Early-stage NSCLC.
    Anticancer Res. 2021;41:4571-4575.
    PubMed     Abstract available

  127. MIRKA H, Ferda J, Krakorova G, Vodicka J, et al
    The Use of CT Pattern in Differentiating Non-invasive, Minimally Invasive and Invasive Variants of Lung Adenocarcinoma.
    Anticancer Res. 2021;41:4479-4482.
    PubMed     Abstract available

  128. SUZUKI S, Yamamoto M, Sanomachi T, Togashi K, et al
    Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin.
    Anticancer Res. 2021;41:4321-4331.
    PubMed     Abstract available

    August 2021
  129. GIATROMANOLAKI A, Anestopoulos I, Panayiotidis MI, Mitrakas A, et al
    Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2021;41:3989-3995.
    PubMed     Abstract available

  130. LAFAUY P, Silapech A, Aksorn N, Sritularak B, et al
    Millettocalyxin B Inhibits Migratory Behavior of Lung Cancer Cells via Integrin alpha5 Suppression.
    Anticancer Res. 2021;41:3843-3849.
    PubMed     Abstract available

  131. OTSUKA T, Ueda K, Furukawa T, Koriyama C, et al
    Significance of Mitochondrial DNA Haplogroup on Epidermal Growth Factor Receptor Mutation in Japanese Patients With Lung Adenocarcinoma.
    Anticancer Res. 2021;41:3997-4004.
    PubMed     Abstract available

  132. YAMANAKA M, Hayashi M, Yamada S, Sonohara F, et al
    A Possible Definition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes.
    Anticancer Res. 2021;41:3933-3940.
    PubMed     Abstract available

    July 2021
  133. SHIONOYA Y, Hirohashi Y, Takahashi H, Hashimoto M, et al
    Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report.
    Anticancer Res. 2021;41:3699-3706.
    PubMed     Abstract available

  134. ZAITSU J, Yamashita Y, Ishikawa A, Saito A, et al
    Systemic Inflammatory Score Predicts Response and Prognosis in Patients With Lung Cancer Treated With Immunotherapy.
    Anticancer Res. 2021;41:3673-3682.
    PubMed     Abstract available

  135. JANG SK, Hong SE, Lee DH, Kim JY, et al
    Inhibition of AKT Enhances the Sensitivity of NSCLC Cells to Metformin.
    Anticancer Res. 2021;41:3481-3487.
    PubMed     Abstract available

    June 2021
  136. LEE GD, Chung B, Song JS, Jang SJ, et al
    The Prognostic Value of Programmed Death-ligand 1 (PD-L1) in Patients who Received Neoadjuvant Chemoradiation Therapy Followed by Surgery for Locally Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:3193-3204.
    PubMed     Abstract available

  137. MOHIUDDIN MD, Kasahara K
    Pemetrexed Disodium Heptahydrate Induces Apoptosis and Cell-cycle Arrest in Non-small-cell Lung Cancer Carrying an EGFR Exon 19 Deletion.
    Anticancer Res. 2021;41:2963-2977.
    PubMed     Abstract available

  138. PUTRI HE, Sritularak B, Chanvorachote P
    DS-1 Inhibits Migration and Invasion of Non-small-cell Lung Cancer Cells Through Suppression of Epithelial to Mesenchymal Transition and Integrin beta1/FAK Signaling.
    Anticancer Res. 2021;41:2913-2923.
    PubMed     Abstract available

  139. KIM SY, Jeong EH, Lee TG, Kim HR, et al
    The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells.
    Anticancer Res. 2021;41:2885-2894.
    PubMed     Abstract available

  140. LIU YC, Hsu FT, Chung JG, Weng MC, et al
    Lenvatinib Induces AKT/NF-kappaB Inactivation, Apoptosis Signal Transduction and Growth Inhibition of Non-small Cell Lung Cancer In Vivo.
    Anticancer Res. 2021;41:2867-2874.
    PubMed     Abstract available

    May 2021
  141. MASUDA T, Wakabayashi YU, Nakashima T, Nishimura Y, et al
    Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone.
    Anticancer Res. 2021;41:2661-2667.
    PubMed     Abstract available

  142. OKIMOTO T, Tsubata Y, Tanino R, Nakao M, et al
    ERCC1 Is a Predictive Biomarker for Non-small Cell Lung Cancer But Is Antibody-dependent.
    Anticancer Res. 2021;41:2653-2660.
    PubMed     Abstract available

  143. SUGIURA H, Miki Y, Iwabuchi E, Saito R, et al
    Estrogen Receptor beta Is Involved in Acquired Resistance to EGFR-tyrosine Kinase Inhibitors in Lung Cancer.
    Anticancer Res. 2021;41:2371-2381.
    PubMed     Abstract available

  144. KREJCI D, Opalka P, Krejci J, Zemanova M, et al
    Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment.
    Anticancer Res. 2021;41:2597-2603.
    PubMed     Abstract available

  145. AOKI K, Nagatani Y, Noma K, Tsugawa T, et al
    Effective Control of Brain Metastases Irrespective of Distance from Isocenter in Single-isocenter Multitarget Stereotactic Radiosurgery.
    Anticancer Res. 2021;41:2575-2581.
    PubMed     Abstract available

  146. HISAKANE K, Seike M, Sugano T, Matsuda K, et al
    PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma.
    Anticancer Res. 2021;41:2501-2509.
    PubMed     Abstract available

  147. GUSHO CA, Blank AT
    What Is the Clinical Impact of Sending Tissue for Histopathology During Surgery for Known, Diffuse Metastatic Disease to Bone?
    Anticancer Res. 2021;41:2473-2476.
    PubMed     Abstract available

  148. SHIROSHITA A, Kurosaki M, Takeshita M, Kataoka Y, et al
    Medical Thoracoscopy, Computed Tomography-guided Biopsy, and Ultrasound-guided Biopsy for Malignant Pleural Mesothelioma: A Systematic Review.
    Anticancer Res. 2021;41:2217-2225.
    PubMed     Abstract available

    April 2021
  149. TSUKIOKA T, Izumi N, Komatsu H, Inoue H, et al
    Tumor Size and N2 Lymph Node Metastasis Are Significant Risk Factors for Early Recurrence in Completely Resected Centrally Located Primary Lung Cancer Patients.
    Anticancer Res. 2021;41:2165-2169.
    PubMed     Abstract available

  150. TOZUKA T, Yanagitani N, Yoshida H, Manabe R, et al
    Impact of Renin-angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients.
    Anticancer Res. 2021;41:2093-2100.
    PubMed     Abstract available

  151. SVATON M, Bratova M, Fischer O, Krejci J, et al
    Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study.
    Anticancer Res. 2021;41:2059-2065.
    PubMed     Abstract available

  152. MON MM, Srisomsap C, Chokchaichamnankit D, Watcharatanyatip K, et al
    Serum Proteomic Profiling Reveals Differentially Expressed IGHG3 and A1AG1 as Potential Predictors of Chemotherapeutic Response in Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:1871-1882.
    PubMed     Abstract available

  153. SVATON M, Blazek J, Krakorova G, Pesek M, et al
    Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy.
    Anticancer Res. 2021;41:2053-2058.
    PubMed     Abstract available

  154. SHIBA S, Shibuya K, Okamoto M, Okano N, et al
    Carbon-ion Radiotherapy for Oligometastatic Colorectal Cancer in the Liver or Lung.
    Anticancer Res. 2021;41:1997-2005.
    PubMed     Abstract available

    March 2021
  155. FUKUDA N, Toda K, Ohmoto A, Wang X, et al
    Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib.
    Anticancer Res. 2021;41:1683-1691.
    PubMed     Abstract available

  156. KINOSHITA F, Yamashita T, Oku Y, Kosai K, et al
    Prognostic Impact of Albumin-bilirubin (ALBI) Grade on Non-small Lung Cell Carcinoma: A Propensity-score Matched Analysis.
    Anticancer Res. 2021;41:1621-1628.
    PubMed     Abstract available

  157. NIEDER C, Mannsaker B, Yobuta R
    Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases.
    Anticancer Res. 2021;41:1471-1474.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.